Skip to main content
SBRA logo

SBRA · Sabra Health Care REIT, Inc.

Track SBRA — free
$20.32 +0.17 (+0.84%) At close · Aug 14
Market Cap
$5.16B
Shares
255.46M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$20.32 Open$19.85 Day$19.71–20.35 52W close$17.23–22.39 Avg vol 30d3.0M Short int24.5M · 9.6% float · 7.4d Short vol44% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 3

Up next

Next earnings call
Nov 7, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 3, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Fair Quant / Vol Low
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +3%
      above
      Price vs 50-day avg +2%
      above
      RSI (14) 46
      neutral
      MACD trend Negative
      52-week position 60%
      mid-range
      Momentum
      relative strength
      Neutral
      1-month return +1%
      trailing
      6-month return −1%
      trailing
      YTD return +7%
      this year
      Relative strength −14%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $20 › 200d $20 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +50 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      9.60% of float · ▼ -1.8% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      455 holders — near 3-yr high, broad support
      Squeeze score 65
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth +10%
      Y/Y
      EPS growth +19%
      Y/Y
      Valuation P/E 77.7
      rich
      Balance sheet $2.5B
      net debt
      Quant / Vol
      risk profile
      Low
      Volatility 25%
      annualized · 1-yr
      Max drawdown −17%
      past year
      ATR 2.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Feb 12, 2026
      Net Income · 2026 $0.60 – $0.64
      FFO · 2026 $1.49 – $1.53
      Normalized FFO · 2026 $1.49 – $1.53
      AFFO · 2026 $1.55 – $1.59
      Normalized AFFO · 2026 $1.55 – $1.59
      Prior guidance period ended · from the 8-K filed Nov 5, 2025
      Net Income · 2025 $0.66 – $0.67
      FFO · 2025 $1.47 – $1.48
      Normalized FFO · 2025 $1.46 – $1.47
      AFFO · 2025 $1.46 – $1.47
      Normalized AFFO · 2025 $1.50 – $1.51

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +3% Bullish
      Price vs 50-day avg
      +2% Bullish
      RSI (14)
      46 Neutral
      MACD trend
      Negative Bearish
      52-week position
      60% Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $20 › 200d $20 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +50 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      9.60% of float · ▼ -1.8% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      455 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $17 Now $20 · 60% Range high $22
      vs 200-day avg +3% vs 50-day avg +2%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Behavioral health facilities 16 As of June 30, 2026
      Investments in loans receivable 11 As of June 30, 2026
      Real estate properties held for investment 364 As of June 30, 2026
      Senior housing - leased communities 32 As of June 30, 2026
      Senior housing - managed communities 94 As of June 30, 2026
      Skilled nursing/transitional care facilities 207 As of June 30, 2026
      Specialty hospitals and other facilities 15 As of June 30, 2026
      Beds/units 36,412 Q1 2026
      Adjusted EBITDA, as adjusted non-GAAP $123.9M Three Months Ended December 31, 2025
      Adjusted EBITDA, as adjusted, annualized non-GAAP $495.61M As of December 31, 2025
      Net Debt non-GAAP $2.48B As of December 31, 2025

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      REIT - Healthcare Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      SBRA
      Sabra Health Care REIT, Inc.
      this stock
      $5.16B +7.3% +10.2% 77.7 9.6%
      WELL
      Welltower Inc.
      $162.55B +26.9% +35.6% 114.6 2.5%
      VTR
      Ventas, Inc.
      $45.66B +18.3% +18.5% 164.8 4.6%
      DOC
      Healthpeak Properties, Inc.
      $14.34B +29.3% +4.5% 59.4 3.5%
      OHI
      Omega Healthcare Investors Inc
      $13.90B +4.9% +13.2% 16.3 4.2%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      455
      % held
      101.9%
      Net QoQ
      +1.5M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      589
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      24.5M
      Days to cover
      7.4d
      Change
      -450.3K sh
      View
      Short Volume
      Short vol %
      44%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      3.3K
      Value
      $63.9K
      As of
      Jul 1, 2026
      View
      Off-Exchange
      Off-exchange %
      38.2%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Daniel Goldman
      Amount
      $1.0K–$15.0K
      Traded
      Apr 10, 2023
      View
      Financials
      Financials
      Revenue (FY)
      $774.6M
      Net income (FY)
      $155.6M
      EPS diluted
      $0.64
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 3, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $192.5K
      Shares
      11.0K
      Filed
      May 15, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 4, 2026
      View
      Investor Relations
      Latest news
      Sabra Reports Second Quarter 2026…
      Published
      Aug 3, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      SBRA -3.4% +1.0% -0.5% -4.0% +7.3%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -3.8% -3.4% -14.3% -7.9% -6.6%

      Capital returns

      Latest dividend
      $0.30 / share · ex Aug 14, 2026
      Cut 33.3%
      Paid (TTM)
      $1.20 / share · 4 payouts
      Dividend yield (TTM, derived)
      5.91%

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1492298 CUSIP 78573L106 13F (30d) 430 filings 426 filers Visit website Investor relations